09.09.25 -- STREAM Edition: Revolutionizing Cell Therapy Manufacturing With AI

In this session, Joyce Ji and Eric Simmons highlight how their fill finish solutions offer detailed customization and industry-leading supply assurance. Learn how the BioTitan retention device enhances aseptic fill finish processes by preventing leaks, and how the Q10 integrity tester safeguards assemblies, detecting pinholes as small as 10 microns. Their insights spotlight industry-leading approaches to downstream success. Watch the presentation to learn more.

Discover how AI can optimize processes, improve efficiency, and enhance the understanding of cellular processes, ultimately leading to more effective and personalized patient treatments.

Explore the final chapter of our webinar series, where we tackle the complexities of scaling shear-sensitive cell therapy manufacturing and discover practical solutions to streamline your process.

In this roundtable discussion, a trio of distinguished experts in AAV purification and process development share their expertise and best practices in tackling and solving downstream challenges.

Discover a platform that reduces operator errors and batch failures through automation and intelligent design to ensure greater process reliability and consistent outcomes in your workflow.

Explore how a biosciences company has used their Curator™ adherent platform to manufacture more than 450 Phase 1 and 2 clinical batches, covering a variety of serotypes and indications.

Tighter integration between research, process development, and manufacturing is key to accelerating the translation of cell therapies from the lab to the clinic. Learn how a leading academic center is doing it.

This is Episode 4 of "FDA Fridays," a special series from Cell & Gene: The Podcast, Chief Editor Erin Harris speaks with regulatory affairs expert Daniela Drago, Partner, NDA Partners, about how shifting FDA and CBER priorities under the current administration could influence the trajectory of cell and gene therapy development.